Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice. (23rd November 2018)

• Record Type: Journal Article
• Authors: Park, Sung-Soo; Eom, Hyeon-Seok; Kim, Jin Seok; Koh, Youngil; Choi, Chul Won; Lee, Je-Jung; Kim, Kihyun; Suh, Cheolwon; Lee, Jae Hoon; Min, Chang-Ki
• Is Part Of: Japanese journal of clinical oncology. Volume 49:Number 1(2019)
• Page Start: 92
• Page End: 95
• Publication Date: 2018-11-23
• Subjects: CD38 -- Daratumumab -- relapsed -- refractory -- multiple myeloma; Oncology -- Periodicals; Cancer -- Periodicals; 616.994005
• DOI: 10.1093/jjco/hyy177
• Languages: English
• ISSNs: 0368-2811

Abstract

Abstract : Following daratumumab monotherapy for relapsed/refractory multiple myeloma, a favorable outcome in overall response rate (56.3%) with a median progression-free survival of 2.7 months was observed despite a high frequency of infectious events. Abstract: Despite the recently reported efficacy of daratumumab monotherapy for patients with relapsed or refractory multiple myeloma, outcomes in real practice following daratumumab monotherapy have yet to be investigated. A multi-center retrospective study of 16 Korean patients receiving daratumumab monotherapy for relapsed or refractory multiple myeloma was conducted. The overall response rate was 56.3%. Three patients with creatinine clearance <30 ml/min even achieved an overall response. The median progression-free survival was 2.7 months with 28.9% (95% CI, 9.0–52.8) of 6-month progression-free survival. All infusion-related reactions, including ≥Grade 3 back pain (6.3%) and dyspnea (6.3%), were manageable. The most common hematologic and non-hematological adverse events were anemia (62.5%) and upper respiratory infection (43.8%). ≥Grade 3 bacterial infectious adverse events were identified, including upper and lower respiratory infection (12.5% and 18.8%) and death following sepsis (6.3%). We observed acceptable outcomes of daratumumab monotherapy on relapsed or refractory multiple myeloma patients including even a few subjects with high comorbidity, despite relatively frequent infectious adverse events.